US 2016/0243124 A1Published application

Method for treating acute myeloid leukemia

AssigneeBoehringer Ingelheim International GmbH

InventorsTillmann TAUBE, Gerd Michael MUNZERT, Dorothea Ingrid RUDOLPH

Life of this patent

Estimating the term…

Abstract

The present invention relates to the use of BI 6727 or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) comprising the administration of a high dose of BI 6727 according to a specific dosage schedule, optionally in combination with cytarabine.

Claims12

Dependent claims

A method of treating acute myeloid leukemia (AML) comprising administering 350 to 500 mg of BI 6727 or a pharmaceutically acceptable salt thereof or a hydrate thereof to a patient suffering from AML.

Dependencies are inferred from the claim text.

Facts

Application: 15/147,037Filed 5 May 2016
Priority: EP 10192956.029 Nov 2010
Published: 25 Aug 2016
Term ends: Not estimatedThe source records don’t support an estimate.

Classification7 codes

A61K 31/519
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: ortho- or peri-condensed with heterocyclic rings
A61K 31/7068
Containing condensed or non-condensed pyrimidines: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61P 35/02
Antineoplastic agents: specific for leukemia
A61P 43/00
Drugs for specific purposes, not provided for in groups a61p1/00-a61p41/00

Family

Application13/297,309Continuation · filed 16 Nov 2011
Application15/147,037Continuation
US 2012/0295864 A1Published application
US 9,358,233 B2Related patent
US 2016/0243124 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results